Slides
Page 1
Investor Presentation January 2026
Page 2
#578583 #4D0E60 #F3A536 #3F4851 #BBBBBB #F2F2F2 Safe Harbor Statement 2 This presentation and the related conference call and webcast contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek’s expected revenue for the fourth quarter and full year ended December 31, 2025; Cytek’s market position and long-term market expansion opportunities; Cytek’s business, product and operational goals and strategies; and Cytek’s opportunities for growth and profitability. Cytek’s audited financial results for the full year ended December 31, 2025 are not yet available and its preliminary expectations regarding revenue for the period are subject to review by Cytek’s management and audit by Cytek’s independent registered public accounting firm. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. All statements other than statements of historical facts may be forward-looking statements. The words “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Factors that could cause actual results to differ materially include, without limitation, adjustments to the estimate that may be required in connection with the completion of the Company’s year-end closing and auditing procedures and risks and uncertainties relating to global geopolitical, economic and market conditions; Cytek’s ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek's ability to evaluate its prospects for future viability and predict future performance; Cytek’s ability to accurately forecast customer demand and adoption of its products; Cytek’s ability to recognize the anticipated benefits of collaborations; Cytek’s dependence on certain sole and single source suppliers; competition; market acceptance of Cytek’s current and potential products; Cytek’s ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek’s ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek’s ability to increase penetration in its existing markets and expand into adjacent markets; Cytek’s ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek’s ability to successfully develop and introduce new products; Cytek’s ability to maintain, protect and enhance its intellectual property; Cytek’s ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. Information on these and additional risks and uncertainties and other information affecting Cytek’s business and operating results is contained in Cytek’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 5, 2025 and other filings Cytek makes with the SEC from time to time. Unless otherwise indicated, these forward-looking statements speak only as of the date hereof. Except as required by applicable law, Cytek does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Cytek, FSP, ESP, Cytek Northern Lights, Northern Lights, Cytek Aurora, Cytek Orion, cFluor, Tonbo, Amnis, Guava, Muse, and DxP Athena are trademarks of Cytek Biosciences, Inc. Other trademarks appearing in this presentation are the property of their respective holders.
Page 3
#578583 #4D0E60 #F3A536 #3F4851 #BBBBBB #F2F2F2 Empowering scientific communities with leading cell analysis tools 3
Page 4
#578583 #4D0E60 #F3A536 #3F4851 #BBBBBB #F2F2F2 Cytek 2025 at a Glance (1) Broad Customer Base & Global Presence >2,000 Customers >70 Countries Validated Technology Platform 3,456 Units Placed >3,200 Cytek FSP Peer- reviewed Publications Strong Financial Profile ~$201M (2) 2025 Total Revenue (est.) ~$262M Cash & Marketable Securities 4 1. All metrics, excluding 2025 revenue, as of 9/30/2025 2. Preliminary, unaudited revenue results announced on 1/12/2026 are not a comprehensive statement of Cytek’s financial results, and Cytek’s actual revenue may differ from the estimate
Page 5
#578583 #4D0E60 #F3A536 #3F4851 #BBBBBB #F2F2F2 Fremont (Headquarters) Bethesda Shanghai Wuxi Amsterdam Tokyo San Diego Seattle Singapore 1. YTD as of 9/30/25 2. EMEA = Europe, Middle East, & Africa 3. APAC = Asia-Pacific; Rest of World = Canada, Latin America, and other non-specified regions Global Scale and Reach with Diversified Revenue Mix (1) % Revenue by Industry USA 50% EMEA(2) 26% APAC & ROW (3) 24% 41% 59% Academic and Government-Owned Institutions Pharma and Biotech, Distributors and CROs 5
Page 6
#578583 #4D0E60 #F3A536 #3F4851 #BBBBBB #F2F2F2 Large and Growing Global Cell Analysis Market Addressable by Flow Cytometry (1) 6 1. The Market Reports (2025); https://www.themarketreports.com 2. TAM = Total Addressable Market $5.1B $9.2B 2032 Forecasted TAM 2025 TAM (2) 8.8% Global CAGR 2025-2032
Page 7
#578583 #4D0E60 #F3A536 #3F4851 #BBBBBB #F2F2F2 Our Strategic Business Pillars 7 Instruments Applications Bioinformatics Clinical (1) Performance RegulatoryCytek CloudReagents Intelligence LDTAnalysis / AIEnabler Harmonization Menu DrivenOptimizationFlexibility Reliability AIManagementFunctionality Cost Effective StandardizationExchangesRecurring Revenue 1. Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).
Page 8
#578583 #4D0E60 #F3A536 #3F4851 #BBBBBB #F2F2F2 Reagents Broad Portfolio of Best-in-Class Cell Analysis Tools 8 Instruments Applications Bioinformatics Clinical Aurora Evo Cytek Aurora Aurora Cell Sorter Northern Lights Guava Muse Micro Amnis Cytek Cloud Services
Page 9
#578583 #4D0E60 #F3A536 #3F4851 #BBBBBB #F2F2F2 Northern Lights >24 Colors from 1-3 Lasers High-Throughput & Compact 9 Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union). Instruments Applications Bioinformatics Clinical Individual Researchers & Clinical Labs Entry-Level Market Aurora Evo / Aurora Analyzer 50+ Colors from 3-5 Lasers Biopharma, CROs, Large Academic Labs High-End Market Aurora Cell Sorter 50+ Colors from 3-5 Lasers Biopharma, CROs, Large Academic Labs Sub-Cellular Particle Detection Flexible & Intuitive Ultra- Sensitive Valuable Insights Data Harmonization Essential Lab Tools: Analyzer to Sorter Underpinned by FSP Technology
Page 10
#578583 #4D0E60 #F3A536 #3F4851 #BBBBBB #F2F2F2 Reagents & Kits Driving Recurring Revenue Growth Reagent revenue grew ~21% y/y in Q3 2025 Instruments Applications Bioinformatics Clinical Fluorochrome conjugated antibodies used to identify cells of interest Multi-color kits and panels give users ready-to-use antibodies and protocols 1- and 2-Laser 6-Color TBNK Reagents Approved for Clinical Use in China CE-IVD single-color & 6-color TBNK reagents for EU customers 10 Research Areas: Immuno- oncology, Infectious Diseases and Inflammatory Diseases Workflows: Drug Discovery, Genomics and Immunoprofiling
Page 11
#578583 #4D0E60 #F3A536 #3F4851 #BBBBBB #F2F2F2 Cytek Cloud: OS Delivering End-to-End Integrated Solution for Cytek Tools 11 Functionalities >22,600 Users Grew user base by 40% since start of 2025 (1) 1. Metrics as of 9/30/2025 Instruments Applications Bioinformatics Clinical Enhanced Panel Design Capabilities Experimental Design Data Analysis Data Storage and User Management Simplifies complex research with streamlined experiment workflow Saves researchers days to months in designing complex panels Unlocks significant cost savings with simulated experiments Creates value and deepens customer engagement with paid licenses Drives more use of Cytek cell analysis solution, reagent and services
Page 12
#578583 #4D0E60 #F3A536 #3F4851 #BBBBBB #F2F2F2 Preliminary 2025 Revenue Results (1) 12 $13.3 $14.2 $14.2 $28.1 $31.4 $38.1 Q1 2025 Q2 2025 Q3 2025 Q4 2025 $41.5 -8% Y/Y $45.6 -2% Y/Y $52.3 +2% Y/Y ~$62M ~+8% Y/Y Q4 showed meaningful acceleration in Y/Y quarterly revenue growth compared to prior quarters in 2025 Driven by: • Continued growth of global Service & Reagents, and APAC instruments • Recovery in EMEA instruments • Continued improvement in US 2025 CommentaryService Revenue Product Revenue 1. Preliminary, unaudited revenue results announced on 1/12/2026 are not a comprehensive statement of Cytek’s financial results, and Cytek’s actual revenue may differ from the estimate.
Page 13
#578583 #4D0E60 #F3A536 #3F4851 #BBBBBB #F2F2F2 13 Driving Continuous Technology Innovation 2016 DXP Athena® System 2017 Cytek Aurora Analyzer 2018 Northern Lights Analyzer 2020 cFluor® Reagents 2021 Cytek Aurora Cell Sorter Tonbo Reagents (3) 2022 CE-IVDD 2024 ESP Detection Option 2025 Cytek Aurora Evo Analyzer Cytek Muse® Micro Cell Analyzer 2023 StarBright Reagents (1) Amnis® & Guava® Products (2) Cytek Orion Mixer 1. Announced partnership with Bio-rad use of StarBright dye portfolio in February 2023 2. Acquired from Luminex in February 2023 3. Acquired form Tonbo in November 2021
Page 14
#578583 #4D0E60 #F3A536 #3F4851 #BBBBBB #F2F2F2 2026 Growth Drivers 14 Innovative new products Conventional flow cytometer replacement cycle Growth in installed base to drive Service growth Growth in Reagents driven by expanding market share Clinical expansion in EMEA and in China Cytek Cloud to improve workflows and utilization Flow cytometry market growth
Page 15
#578583 #4D0E60 #F3A536 #3F4851 #BBBBBB #F2F2F2 15 Well-positioned for Growth and Profitability Technology Platform Leader Strengthening market leadership position through innovative new products that will reinforce our competitive position and accelerate growth Global Diversification Multiple geographies with instrument and recurring revenue streams Growing Recurring Revenue Reagent and service businesses benefitting from established and expanding global installed base Attractive Financial Profile Well-positioned to deliver long-term value through differentiated technology portfolio, durable growth drivers, strong balance sheet, and global reach
Page 16
#578583 #4D0E60 #F3A536 #3F4851 #BBBBBB #F2F2F2 Thank You 16